Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases.
2004
Abstract Phosphodiesterases (PDEs) comprise a large family of enzymes that catalyze the hydrolysis of cAMP or cGMP and are implicated in various diseases. We describe the high-resolution crystal structures of the catalytic domains of
PDE4B, PDE4D, and PDE5A with ten different inhibitors, including the drug candidates
cilomilastand
roflumilast, for respiratory diseases. These
cocrystalstructures reveal a common scheme of inhibitor binding to the PDEs: (i) a hydrophobic clamp formed by highly conserved hydrophobic residues that sandwich the inhibitor in the active site; (ii) hydrogen bonding to an invariant glutamine that controls the orientation of inhibitor binding. A scaffold can be readily identified for any given inhibitor based on the formation of these two types of conserved interactions. These structural insights will enable the design of isoform-selective inhibitors with improved binding affinity and should facilitate the discovery of more potent and selective PDE inhibitors for the treatment of a variety of diseases.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
45
References
308
Citations
NaN
KQI